HeartBeam (NASDAQ: BEAT) Launches Proposed Public Offering to Support Commercialization and AI Initiatives

At a glance

Company: HeartBeam
Ticker: NASDAQ: BEAT
Announcement: Financing

Products and programs

12-lead synthesized ECG system
Extended-wear patch
Heart attack detection initiatives

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it is commencing an underwritten public offering of shares of its common stock or common stock equivalents, with all securities to be offered by the company and the final size and terms subject to market conditions. The company said it intends to use net proceeds from the offering to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection initiatives, enhance its AI capabilities and support working capital and general corporate purposes, with Titan Partners, a division of American Capital Partners, acting as sole bookrunner.

To view the full press release, visit https://ibn.fm/pxFOz

About HeartBeam, Inc.

HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The Company holds over 20 issued patents related to technology enablement.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

In brief

HeartBeam says it has begun an underwritten public offering of its common shares or common-stock equivalents. The company will issue all securities in the offering, while its size and terms remain subject to market conditions. HeartBeam expects to use net proceeds for commercialization of its FDA-cleared 12-lead synthesized ECG system, development of an extended-wear patch and heart attack detection initiatives, and improvements to its AI capabilities. Proceeds may also support working capital and general corporate purposes. Titan Partners, a division of American Capital Partners, is serving as sole bookrunner. The release describes HeartBeam as a medical technology company focused on cardiac care and says its technology has received FDA clearances for arrhythmia assessment and 12-lead ECG synthesis.

Key takeaways

HeartBeam has launched an underwritten offering of common shares or common-stock equivalents.
The company will offer all securities; offering size and terms depend on market conditions.
Planned uses include commercialization, product and AI development, working capital, and general corporate purposes.
Titan Partners is acting as sole bookrunner.

SEC filings

Earlier from HeartBeam, Inc.

Back to News Center